ponalrestat has been researched along with Diabetes Mellitus in 11 studies
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To update readers on research being conducted with the aldose reductase inhibitor (ARI) tolrestat in treating complications of diabetes mellitus." | 4.78 | Aldose reductase inhibitors: an update. ( Burnakis, TG; Tsai, SC, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coleman, MD | 1 |
| Simpson, J | 1 |
| Jacobus, DP | 1 |
| Cameron, NE | 1 |
| Cotter, MA | 1 |
| Tsai, SC | 1 |
| Burnakis, TG | 1 |
| Nishinaka, T | 1 |
| Yabe-Nishimura, C | 1 |
| Collier, A | 1 |
| Small, M | 1 |
| Price, DE | 2 |
| Alani, SM | 1 |
| Wales, JK | 2 |
| Moulds, RF | 1 |
| Fullinfaw, RO | 1 |
| Bury, RW | 1 |
| Plehwe, WE | 1 |
| Jacka, N | 1 |
| McGrath, KM | 1 |
| Martin, FI | 1 |
| Vicario, PP | 1 |
| Slater, EE | 1 |
| Saperstein, R | 1 |
| Airey, CM | 1 |
| Kemp, JV | 1 |
| Perkins, CM | 1 |
| Hotta, N | 1 |
| Sakamoto, N | 1 |
| Kador, PF | 1 |
| Kinoshita, JH | 1 |
| Sharpless, NE | 1 |
3 reviews available for ponalrestat and Diabetes Mellitus
| Article | Year |
|---|---|
Aldose reductase inhibitors: an update.
Topics: Aldehyde Reductase; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Humans; Imi | 1993 |
[Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
Topics: Aldehyde Reductase; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies | 1987 |
Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Topics: Aldehyde Reductase; Animals; Binding Sites; Blood Glucose; Cataract; Chemical Phenomena; Chemistry; | 1985 |
3 trials available for ponalrestat and Diabetes Mellitus
| Article | Year |
|---|---|
Effect of aldose reductase inhibition on resistance to ischemic conduction block in diabetic subjects.
Topics: Aldehyde Reductase; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double- | 1991 |
Ponalrestat does not cause a protein binding interaction with warfarin in diabetic patients.
Topics: Adult; Aldehyde Reductase; Binding, Competitive; Blood Proteins; Chromatography, High Pressure Liqui | 1991 |
The effect of aldose reductase inhibition on erythrocyte polyols and galactitol accumulation in diabetic patients.
Topics: Aldehyde Reductase; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 1989 |
5 other studies available for ponalrestat and Diabetes Mellitus
| Article | Year |
|---|---|
Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. III: Effect of diabetes.
Topics: Dapsone; Diabetes Mellitus; Ditiocarb; Erythrocytes; Glutathione; Humans; Imidazoles; Imidazolidines | 1994 |
Contraction and relaxation of aortas from galactosaemic rats and the effects of aldose reductase inhibition.
Topics: Aldehyde Reductase; Animals; Aorta; Diabetes Mellitus; Galactosemias; Male; Phthalazines; Rats; Rats | 1993 |
EGF receptor-ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress.
Topics: Aldehyde Reductase; Animals; Cell Line; Cell Survival; Diabetes Complications; Diabetes Mellitus; Er | 2001 |
The role of the polyol pathway in diabetes mellitus.
Topics: Aldehyde Reductase; Diabetes Complications; Diabetes Mellitus; Glycolysis; Glycosylation; Humans; Hy | 1991 |
The effect of ponalrestat on sorbitol levels in the lens of obese and diabetic mice.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Insu | 1989 |